CA2800595C - Compositions comprenant le domaine nc2 du collagene ix et leurs procedes d'utilisation - Google Patents

Compositions comprenant le domaine nc2 du collagene ix et leurs procedes d'utilisation Download PDF

Info

Publication number
CA2800595C
CA2800595C CA2800595A CA2800595A CA2800595C CA 2800595 C CA2800595 C CA 2800595C CA 2800595 A CA2800595 A CA 2800595A CA 2800595 A CA2800595 A CA 2800595A CA 2800595 C CA2800595 C CA 2800595C
Authority
CA
Canada
Prior art keywords
collagen
domain
seq
heterologous
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2800595A
Other languages
English (en)
Other versions
CA2800595A1 (fr
Inventor
Hans Peter Bachinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shriners Hospitals for Children
Original Assignee
Shriners Hospitals for Children
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shriners Hospitals for Children filed Critical Shriners Hospitals for Children
Publication of CA2800595A1 publication Critical patent/CA2800595A1/fr
Application granted granted Critical
Publication of CA2800595C publication Critical patent/CA2800595C/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6435—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin or gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B24/00—Use of organic materials as active ingredients for mortars, concrete or artificial stone, e.g. plasticisers
    • C04B24/12—Nitrogen containing compounds organic derivatives of hydrazine
    • C04B24/14—Peptides; Proteins; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Ceramic Engineering (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Materials Engineering (AREA)
  • Structural Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
CA2800595A 2010-05-26 2011-05-25 Compositions comprenant le domaine nc2 du collagene ix et leurs procedes d'utilisation Expired - Fee Related CA2800595C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34873510P 2010-05-26 2010-05-26
US61/348,735 2010-05-26
PCT/US2011/037923 WO2011150073A2 (fr) 2010-05-26 2011-05-25 Compositions comprenant le domaine nc2 du collagène ix et leurs procédés d'utilisation

Publications (2)

Publication Number Publication Date
CA2800595A1 CA2800595A1 (fr) 2011-12-01
CA2800595C true CA2800595C (fr) 2018-04-24

Family

ID=45004767

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2800595A Expired - Fee Related CA2800595C (fr) 2010-05-26 2011-05-25 Compositions comprenant le domaine nc2 du collagene ix et leurs procedes d'utilisation

Country Status (3)

Country Link
US (2) US9315561B2 (fr)
CA (1) CA2800595C (fr)
WO (1) WO2011150073A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011150073A2 (fr) * 2010-05-26 2011-12-01 Shriners Hospitals For Children Compositions comprenant le domaine nc2 du collagène ix et leurs procédés d'utilisation
US11491154B2 (en) 2013-04-08 2022-11-08 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
WO2017019806A2 (fr) * 2015-07-27 2017-02-02 Michael Fox Collagène xix, formulation de celui-ci et procédés de traitement de troubles associés aux synapses neuronales

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925736A (en) * 1995-01-10 1999-07-20 Fibrogen, Inc. Collagen-based methods and formulations for the treatment of arthritis
BR9611547A (pt) * 1995-11-13 1999-06-15 Fibrogen Inc Proteína de fusão processos para produzir proteína de fusão humana recombinante e colágeno tipo ix humano recombinante
US7268116B2 (en) * 2003-10-02 2007-09-11 Genhunter Corp. Methods and compositions for producing secreted trimeric receptor analogs and biologically active fusion proteins
US7405037B2 (en) * 2004-05-07 2008-07-29 Lonza Walkersville, Inc. Methods and tools for detecting collagen degradation
BRPI0615065A2 (pt) * 2005-09-02 2011-05-03 Colbar Lifescience Ltd processos para a preparação de polissacarìdeos reticulados, os referidos polissacarìdeos, processo para a preparação de uma matriz reticulada compósita, e a referida matriz
US20070264687A1 (en) * 2005-12-15 2007-11-15 Min-Yuan Chou Recombinant triplex scaffold-based polypeptides
WO2011150073A2 (fr) * 2010-05-26 2011-12-01 Shriners Hospitals For Children Compositions comprenant le domaine nc2 du collagène ix et leurs procédés d'utilisation

Also Published As

Publication number Publication date
US20160222089A1 (en) 2016-08-04
US20130157257A1 (en) 2013-06-20
US9932390B2 (en) 2018-04-03
WO2011150073A2 (fr) 2011-12-01
CA2800595A1 (fr) 2011-12-01
US9315561B2 (en) 2016-04-19
WO2011150073A3 (fr) 2012-04-05

Similar Documents

Publication Publication Date Title
AU2008281913B2 (en) New albumin binding compositions, methods and uses
KR100484084B1 (ko) 키메라성 폴리펩타이드, 이의 제조 방법 및 용도
JP3836865B2 (ja) 三量体化ポリペプチド、その製造及び使用
US11345722B2 (en) High pH protein refolding methods
JP2019506163A (ja) 例外的なスプライシング活性を有するスプリットインテイン
US11053278B2 (en) Tangential flow filtration based protein refolding methods
US9932390B2 (en) Compositions comprising the NC2 domain of collagen IX and methods of using same
JP4019432B2 (ja) ヒトアクチビンａのリフォールディング方法
Guo et al. Intein-mediated fusion expression, high efficient refolding, and one-step purification of gelonin toxin
EP1024192B1 (fr) Streptokinases spécifiques du thrombus à la coagulation possédant des charactéristiques d'activation du plasminogène modifiées et un procédé pour leur préparation
Beitle et al. One-step purification of a model periplasmic protein from inclusion bodies by its fusion to an effective metal-binding peptide
Gustafsson et al. Purification of truncated and mutated chemotaxis inhibitory protein of Staphylococcus aureus—an anti-inflammatory protein
Tan et al. Expression and purification of a difficult sarcomeric protein: Telethonin
JPH04234988A (ja) ヒトプロラクチン−プロテインａ融合蛋白発現遺伝子
Betton Using Maltose-Binding Protein Fragment Complementation to Probe Protein-Protein Interactions by Co Expression in the RTS System
Kang et al. Heterologous expression and purification of anglerfish somatostatin precursors in Escherichia coli
LT6389B (lt) Dimerinis antikūno fragmentas, neutralizuojantis vaginolizino citolitinį aktyvumą

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20121211

MKLA Lapsed

Effective date: 20190527